|
IL7RA haplotypes
|
Adjusted
|
|---|
|
rs6897932
|
rs987106
|
rs3194051
|
Freq.
|
Outcomes
|
aOR (95% CI)
|
p value
|
|---|
|
C
|
T
|
A
|
47.9%
|
F ≥ 3
|
2.01 (1.19;3.40)
|
0.007
|
| | | | |
APRI ≥1.5
|
1.98 (1.06;3.71)
|
0.028
|
| | | | |
FIB4 ≥3.25
|
2.69 (1.10;6.60)
|
0.023
|
| | | | |
A3
|
NA
|
–
|
|
C
|
A
|
G
|
31.5%
|
F ≥ 3
|
0.42 (0.22;0.78)
|
0.004
|
| | | | |
APRI ≥1.5
|
0.45 (0.22;0.94)
|
0.026
|
| | | | |
FIB4 ≥3.25
|
0.24 (0.07;0.76)
|
0.007
|
| | | | |
A3
|
NA
|
–
|
|
T
|
A
|
A
|
20.1%
|
F ≥ 3
|
0.86 (0.44;1.67)
|
0.647
|
| | | | |
APRI ≥1.5
|
0.92 (0.42;2.04)
|
0.838
|
| | | | |
FIB4 ≥3.25
|
1.07 (0.35;3.26)
|
0.904
|
| | | | |
A3
|
NA
|
–
|
- P values were calculated by multivariate logistic regression adjusted by the most important clinical and epidemiological characteristics (see “Statistical analysis” section). Statistically significant differences are shown in italics.
-
95% CI 95% of confidence interval, aOR adjusted odds ratio, p value level of significance, A3 severe activity grade (Metavir), F ≥ 3 advanced liver fibrosis (Metavir), APRI aspartate aminotransferase to platelet ratio index, NA not available due to a low number of patients in one of the groups.
